ONGC is actively engaging with international regulators to resume operations in Russia and Venezuela while maintaining domestic growth through technical partnerships and a 15% OPEX reduction target.
Team Sahi
Market snapshot: Oil and Natural Gas Corporation (ONGC) is signaling a robust recovery phase following its Q3 FY26 earnings call. While domestic performance remains steady, the focus has shifted toward its international arm, ONGC Videsh (OVL), and the potential resumption of operations in sanctions-hit regions like Russia and Venezuela. The company reported a consolidated net profit of ₹10,015.7 crore for the quarter ended December 2025, marking a 16.7% YoY increase despite flat revenue growth of 0.1%. Investors are particularly keen on the management's efforts to recover nearly $950 million in trapped funds across global jurisdictions.
Summary: ONGC is actively engaging with international regulators to resume operations in Russia and Venezuela while maintaining domestic growth through technical partnerships and a 15% OPEX reduction target.
ONGC’s pivot from a domestic-heavy E&P focus to a globally diversified strategy reflects a mature risk-appetite. By pursuing US licenses and alternative currency payments (roubles), ONGC is positioning itself to capitalize on high-potential assets that have been dormant. The lifting of force majeure in Mozambique and progress in the Sakhalin-1 transfer suggests that the 'geopolitical discount' on the stock may soon begin to narrow as these cash flows are unlocked.
ONGC's resilience in navigating complex sanctions while delivering double-digit profit growth makes it a central pillar for India's energy security and a value play for dividend seekers.
High Performance Trading with SAHI.
Synthetically modified: AI-generated content by Sahi Live News Engine.
Related
Recent
Fed's 2026 Outlook: Economic Resilience Meets Persistent Inflationary Pressures
Geopolitical Brinkmanship: Trump-Iran Tensions and the Indian Market Outlook
Zydus Lifesciences Disrupts Respiratory Care with India’s First Drug-Free Device 'Pepair' at ₹990
Infosys Pivots to 'AI-First' Era: New Framework Targets $300 Billion Market Opportunity
Zydus Lifesciences Disrupts Respiratory Care with India’s First Affordable Drug-Free Device ‘PepairTM’ at ₹990